Krista Lanctot, PhD: Addressing Alzheimer Disease AgitationSeptember 25th 2018
The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.
Irina Pikuleva, PhD: Using Efavirenz in Alzheimer DiseaseSeptember 24th 2018
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.
Paul Newhouse, MD: Exploring VU319 in Alzheimer DiseaseSeptember 20th 2018
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.
Ronald Crystal, MD: APOE2 Gene Therapy for Alzheimer DiseaseSeptember 17th 2018
The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.
Kelvin Tsoi, PhD: Combination Therapy, Monotherapy in Alzheimer DiseaseAugust 23rd 2018
After identifying and reviewing 76 randomized trials, combination therapy with memantine and AChEIs is confirmed to have no additional benefits over monotherapy.
Lutz Frolich, MD, PhD: Collaboration Between Clinicians and IndustryAugust 18th 2018
Lutz Frölich, MD, PhD, discussed the imperativeness of collaboration between stakeholders—clinicians, pharmaceutical companies, researchers—in developing therapies for Alzheimer disease.
Nir Lipsman, MD, PhD: Innovations in Alzheimer DiseaseAugust 17th 2018
The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.
Gill Livingston, MBChB, MD: Challenges of Sleep Difficulties in People Living with DementiaAugust 16th 2018
Livingston spoke to a number of topics in the dementia space, including the challenges clinicians face and her hope for the future.
Lutz Frolich, MD, PhD: Tempering Expectations for Alzheimer Disease AdvancementsAugust 16th 2018
The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health talked about the biggest challenges facing medicine in treating and understanding Alzheimer disease.
Gill Livingston, MBChB, MD: Manual Based Intervention for Sleep Difficulties in DementiaAugust 15th 2018
DREAMS-START demonstrates that a manual-based psychological treatment for sleep disorders in dementia is feasible and acceptable.
John Didsbury, PhD: Going Against the Grain in Established AlzheimerAugust 14th 2018
The founder and CEO of T3D Therapeutics, Inc., spoke about T3D’s desire to go against the grain and trend in the therapeutic development for mild to moderate Alzheimer disease.
Jeff D. Williamson on the SPRINT MIND TrialAugust 14th 2018
The findings suggest that intensive lowering of blood pressure may reduce the risk of mild cognitive impairment and the combined risk of mild cognitive impairment and dementia, but not dementia alone.
Lutz Frolich, MD, PhD: Target Patient Populations for Alzheimer TherapiesAugust 14th 2018
The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health discussed his thoughts about patients with mild dementia and prodromal Alzheimer disease.
Harald Hampel, MD, PhD, MA, MSc on Advancements and Challenges in the Alzheimer SpaceAugust 13th 2018
Hampel looks to the future of the Alzheimer space and sees promise, especially since there’s transfertilization from other advanced science fields in medicine like oncology, diabetes research and rheumatology.
Samantha Budd Haeberlein, PhD: The TANGO II Trial of BIIB092August 12th 2018
The vice president and head of Alzheimer’s Disease, Dementia, and Movement Disorders in Late Stage Clinical Development at Biogen spoke about the upcoming TANGO II trial in Alzheimer disease.
Davangere Devanand, MBBS, MD: Challenges in Symptom Management in Alzheimer DiseaseAugust 12th 2018
Davangere P. Devanand, MBBS, MD, discussed the possibility of neurologists prescribing low-dose lithium for patients with Alzheimer and symptoms of agitation.
Anton P. Porsteinsson, MD: The s-CitAD Study DesignAugust 11th 2018
The Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program discussed the ongoing study, which is exploring s-citalopram in patients with Alzheimer who also have symptoms of agitation.